Ax­some re­ports de­lay to PhI­II nar­colep­sy study, un­veils peak sales es­ti­mates on its drugs

Ax­some Ther­a­peu­tics ad­just­ed the time­line of a Phase III tri­al for an ex-Pfiz­er drug that it ex­pects to mar­ket for nar­colep­sy by 2025.

The New York-based biotech pro­ject­ed en­roll­ment to wrap up next quar­ter for a tri­al of its in­ves­ti­ga­tion­al nar­colep­sy med, mark­ing a slight de­lay to last month’s guid­ance of hav­ing topline da­ta this quar­ter, per a cor­po­rate deck filed with the SEC on Tues­day.

Ax­some is de­vel­op­ing AXS-12 for the sleep dis­or­der nar­colep­sy and is as­sess­ing whether the twice-dai­ly oral med is bet­ter than place­bo at re­duc­ing the fre­quen­cy of cat­a­plexy, a sud­den mus­cle weak­ness. The com­pa­ny es­ti­mates about 70% of the 185,000 US pa­tients with nar­colep­sy ex­pe­ri­ence cat­a­plexy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER